Drug intelligence / Profile preview

FL923

Development stage: Preclinical
Lead developer: Canget BioTekpharma
Modality: Small Molecules

Overview

FL923 is a preclinical small molecule anticancer agent being developed by Canget BioTekpharma as a backup compound to their lead candidate, FL118. It shares a similar mechanism of action with FL118, a camptothecin-derived molecule, by targeting and degrading the multifunctional oncogenic protein DDX5 (p68). FL923 also inhibits several key anti-apoptotic proteins, specifically survivin, Mcl-1, XIAP, and cIAP2, and is reported to target mutant KRAS (mKras). The drug is primarily positioned for the treatment of pancreatic cancer, aiming to overcome resistance mechanisms associated with these survival pathways.

Targets

DDX5 (Phosphorylated-p68 RNA helicase)DDR (DNA damage response)MCL1 (Myeloid cell leukemia sequence 1)MDM4 (Mouse double minute X homolog)BIRC5 (Survivin)XIAPMYC (MYC proto-oncogene protein)KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on FL923.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FL923.